Role of C-Reactive Protein /Albumin Ratio in Evaluation of Disease Activity in Patients With Inflammatory Bowel Disease

• Sponsor: Assiut University (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05738915
• Collaborator: (none)
• Enrollment: 100
• Anticipated Duration (Months): 5.9

Study Details

Study Description

Brief Summary

Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.

Condition or Disease	Intervention/Treatment	Phase
Inflammatory Bowel Diseases	Diagnostic Test: CRP/Albumin ratio in IBD

Detailed Description

Inflammatory bowel disease (IBD) is defined as a life long chronic inflammatory disease affecting the gastrointestinal tract resulting from the interaction of environmental and genetic elements, has been a global healthcare problem with a steadily increasing incide IBD is mainly composed of two different bowel-relapsing disorders, including Crohn's disease (CD) and ulcerative colitis (UC).

Early detection of the disease activity of IBD is of great significance for the treatment of this disease, which can effectively prevent complications and therefore improve prognosis as well as quality of life. In current clinical practice, commonly used noninvasive biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), are considered to be important for both early diagnosis and accurate monitoring of the disease activity in IBD patients.

The C-reactive protein/albumin ratio (CAR) is indicative of the balance between inflammation and nutritional status, making it an excellent marker for assessing disease activity in patients The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity inde (CDAI).

Study Design

• Study Type: Observational
• Anticipated Enrollment: 100 participants
• Observational Model: Case-Control
• Time Perspective: Retrospective
• Official Title: Role of C-Reactive Protein /Albumin Ratio in Evaluation of Disease Activity in Patients With Inflammatory Bowel Disease
• Anticipated Study Start Date: Feb 15, 2023
• Anticipated Primary Completion Date: Jul 15, 2023
• Anticipated Study Completion Date: Aug 15, 2023

Outcome Measures

Primary Outcome Measures

1. CRP/Albumin ratio in IBD [Baseline]

   Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• patients with IBD which included Crohn disease and Ulcertive colitis patients above age 18 years old.

Exclusion Criteria:

• concurrent infections, liver cirrhosis, hematological diseases, heart failure, malignancies, autoimmune diseases, or congenital or acquired immunodeficiencies

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Mohamed Abd El Raheem, Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease, Assiut University
• ClinicalTrials.gov Identifier: NCT05738915
• Other Study ID Numbers: CRP/Albumin Ratio in IBD
• First Posted: Feb 22, 2023
• Last Update Posted: Feb 22, 2023
• Last Verified: Feb 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Intestinal Diseases; Inflammatory Bowel Diseases

Study Results

No Results Posted as of Feb 22, 2023